Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May 30;16(1):147.
doi: 10.1186/s12967-018-1514-7.

Immunotherapeutic interventions of Triple Negative Breast Cancer

Zehuan Li  1   2 , Yiran Qiu  1   2 , Weiqi Lu  1   2 , Ying Jiang  3   4 , Jin Wang  5
Affiliations
Review

Immunotherapeutic interventions of Triple Negative Breast Cancer

Zehuan Li et al. J Transl Med. .

Abstract

Triple Negative Breast Cancer (TNBC) is a highly heterogeneous subtype of breast cancer that lacks the expression of oestrogen receptors, progesterone receptors and human epidermal growth factor receptor 2. Although TNBC is sensitive to chemotherapy, the overall outcomes of TNBC are worse than for other breast cancers, and TNBC is still one of the most fatal diseases for women. With the discovery of antigens specifically expressed in TNBC cells and the developing technology of monoclonal antibodies, chimeric antigen receptors and cancer vaccines, immunotherapy is emerging as a novel promising option for TNBC. This review is mainly focused on the tumour microenvironment and host immunity, Triple Negative Breast Cancer and the clinical treatment of TNBC, novel therapies for cancer and immunotherapy for TNBC, and the future outlook for the treatment for TNBC and the interplay between the therapies, including immune checkpoint inhibitors, combination of immune checkpoint inhibitors with targeted treatments in TNBC, adoptive cell therapy, cancer vaccines. The review also highlights recent reports on the synergistic effects of immunotherapy and chemotherapy, antibody-drug conjugates, and exosomes, as potential multifunctional therapeutic agents in TNBC.

Keywords: Antibody therapies; Chemotherapy; Exosome; Immunotherapy; Triple Negative Breast Cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Current and potential future immune-related drug targets in TNBC, including immune checkpoint inhibitors, cytokines, and their antibodies
Fig. 2
Fig. 2
Exosomes may serve as a therapeutic option for TNBC. The formation and secretion of exosomes and various types of cancer vaccine therapies and potential vaccine targets for TNBC
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Robert D, Schreiber LJO, Mark J. Smyth: cancer immunoediting integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–1570. doi: 10.1126/science.1203486. - DOI - PubMed
    1. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25. doi: 10.1016/j.coi.2014.01.004. - DOI - PMC - PubMed
    1. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–899. doi: 10.1016/j.cell.2010.01.025. - DOI - PMC - PubMed
    1. Hwang I, Nguyen N. Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects. Arch Pharm Res. 2015;38:1415–1433. doi: 10.1007/s12272-015-0566-y. - DOI - PubMed
    1. Topfer K, Kempe S, Muller N, Schmitz M, Bachmann M, Cartellieri M, Schackert G, Temme A. Tumor evasion from T cell surveillance. J Biomed Biotechnol. 2011;2011:918471. doi: 10.1155/2011/918471. - DOI - PMC - PubMed

Publication types

Substances